{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-011224","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2022-01-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.901072+00:00","generated_at":"2026-06-27T17:36:20.581651+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Krystal Biotech appoints Jing Marantz as CBO, adds Rand Sutherland to board","bullets":["Jing Marantz resigns from board effective Jan 18, 2022, to become Chief Business Officer.","E. Rand Sutherland appointed to board same day; no committee assignments initially.","Marantz previously SVP at Acceleron, Alnylam, Alexion; Sutherland was president of Translate Bio.","Marantz's resignation not due to any disagreement with Krystal.","Both appointments effective January 18, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-011224","json":"https://secwatch.observer/filing/0001193125-22-011224.json","markdown":"https://secwatch.observer/filing/0001193125-22-011224.md","text":"https://secwatch.observer/filing/0001193125-22-011224.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000119312522011224/0001193125-22-011224-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000119312522011224/d294817d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T17:36:20.581651+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"08089bdebf","claim":"E. Rand Sutherland was appointed as Director at Krystal Biotech, Inc..","evidence_excerpt":"On January 13, 2022, the Board appointed E. Rand Sutherland as a member of the Board, effective January 18, 2022, to fill the vacancy created by Dr. Marantz’s resignation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711279/000119312522011224/0001193125-22-011224-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"982b15b19c","claim":"Jing Marantz was appointed as Chief Business Officer at Krystal Biotech, Inc..","evidence_excerpt":"Dr. Marantz will continue to serve as a director of the Company until January 18, 2022, subsequent to which, she has agreed to commence a senior executive position (Chief Business Officer) at the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711279/000119312522011224/0001193125-22-011224-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"commenced"},{"label":"Role","value":"Chief Business Officer"}],"fact_type":"executive_change"},{"claim_id":"eeca00bbf4","claim":"Jing Marantz resigned as Director at Krystal Biotech, Inc..","evidence_excerpt":"On January 12, 2022, Jing Marantz gave notice of her resignation from the Board of Directors (the “Board”) of Krystal Biotech, Inc. (the “Company”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711279/000119312522011224/0001193125-22-011224-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}